BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
- None.
- None.
Insights
The recent public offering by BIOLASE, Inc. represents a strategic move to raise capital, indicative of the company's immediate financial needs or future investment plans. With a sale of 16 million units at $0.44 each, the gross proceeds of approximately $7 million, before fees and expenses, suggest a calculated approach to funding, albeit at a relatively low unit price which could reflect market skepticism or a strategic pricing decision to ensure the offering's success.
Investors should note the immediate exercisability of Class A warrants at $0.66, which is above the offering price and the future exercisability of Class B warrants pending stockholder approval. This structure can potentially lead to dilution of shares but also provides investors with an opportunity to increase their stake in the company at predetermined prices, which could be advantageous if the company's stock price appreciates.
The involvement of established placement agents like Lake Street Capital Markets, LLC and Maxim Group LLC adds a layer of credibility to the offering. However, the low offering price may raise concerns about the company's valuation and the potential impact on existing shareholders' equity.
BIOLASE's decision to raise capital through a public offering is a significant event that can influence its market position. The offering's structure, with common stock and two classes of warrants, is designed to attract a variety of investors, from those seeking immediate equity to those betting on the company's long-term growth with warrants.
The dental laser industry is competitive and BIOLASE's capital infusion could be directed towards research and development, marketing, or expansion strategies to maintain or enhance its market share. The pricing strategy and the terms of the warrants may also signal the company's future growth expectations to the market.
Investors and competitors alike will be watching closely how BIOLASE deploys the raised funds and whether this will translate into increased market penetration or technological advancements that could disrupt the dental laser sector.
From a legal perspective, the offering's compliance with SEC regulations, as evidenced by the effective registration statement, is crucial for investor confidence. The fact that the offering is only made through a prospectus that is part of a registration statement emphasizes the company's commitment to transparency and due diligence.
Furthermore, the clear stipulation that the securities cannot be sold in jurisdictions where it would be unlawful prior to specific registrations or qualifications underlines the legal considerations taken by BIOLASE to ensure the offering's legitimacy. This is an important aspect for investors, as it mitigates legal risks associated with the transaction.
LAKE FOREST, CA / ACCESSWIRE / February 15, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit was sold at an effective public offering price of
Gross proceeds, before deducting placement agent fees and other offering expenses, were approximately
Lake Street Capital Markets, LLC and Maxim Group LLC acted as joint placement agents for the offering.
The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333- 276596) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on February 13, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A copy of the final prospectus relating to the offering has been filed with the SEC and may be obtained from Lake Street Capital Markets, LLC, Attn: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, MN 55402, by calling (612) 326-1305 or Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 patented and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's Annual Report filed on Form 10-K filed with the SEC and other filings by BIOLASE with the SEC. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Investor Relations:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
SOURCE: BIOLASE, Inc.
View the original press release on accesswire.com
FAQ
What is the offering price of each unit in BIOLASE's recent public offering?
How many units were offered in BIOLASE's recent public offering?
What are the details of the Class A Warrants in BIOLASE's recent public offering?
How much did BIOLASE generate in gross proceeds from the public offering?
Who were the joint placement agents for BIOLASE's public offering?
